Bailey Brittany A, Ochyl Lukasz J, Schwendeman Steven P, Moon James J
Department of Pharmaceutical Sciences, Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA.
Department of Biomedical Engineering, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI, 48109, USA.
Adv Healthc Mater. 2017 Jun;6(12). doi: 10.1002/adhm.201601418. Epub 2017 Apr 3.
Poly(lactic-co-glycolic acid) (PLGA) microspheres have been widely examined for vaccine applications due to their attractive features of biocompatibility, biodegradability, ability to be internalized by antigen-presenting cells, and long-term antigen release. However, one of the major challenges for PLGA particle vaccines is the potential for antigen instability and loss of antigenicity and immunogenicity. To address this challenge, we have developed a new method of "self-healing" encapsulation in PLGA microspheres, where pre-made PLGA microspheres are loaded with protein antigens under aqueous conditions with minimal impact on their antigenicity and immunogenicity. In this report, we show that mice immunized with self-encapsulating PLGA microspheres in a prime-boost regimen generated significantly enhanced antigen-specific CD8α+ T cell and antibody responses, compared with mice immunized with free, soluble protein admixed with calcium phosphate gel, a widely used adjuvant. Furthermore, a single-dose of microspheres designed for >40 day sustained antigen release elicited robust cellular and humoral immune responses as efficiently as the prime-boost vaccinations with calcium phosphate gel. Overall, these results suggest excellent potential of our self-encapsulating PLGA microspheres as a vaccine platform for multiple-dose as well as single-dose vaccinations.
聚乳酸-乙醇酸共聚物(PLGA)微球因其具有生物相容性、可生物降解性、能被抗原呈递细胞内化以及可长期释放抗原等吸引人的特性,已被广泛用于疫苗应用研究。然而,PLGA颗粒疫苗面临的主要挑战之一是抗原可能不稳定,导致抗原性和免疫原性丧失。为应对这一挑战,我们开发了一种在PLGA微球中进行“自愈”封装的新方法,即在水性条件下将预先制备的PLGA微球装载蛋白质抗原,同时对其抗原性和免疫原性的影响最小。在本报告中,我们表明,与用与广泛使用的佐剂磷酸钙凝胶混合的游离可溶性蛋白免疫的小鼠相比,在初免-加强免疫方案中用自封装PLGA微球免疫的小鼠产生了显著增强的抗原特异性CD8α+ T细胞和抗体反应。此外,设计用于持续释放抗原超过40天的单剂量微球引发的强大细胞免疫和体液免疫反应,与用磷酸钙凝胶进行初免-加强免疫一样有效。总体而言,这些结果表明我们的自封装PLGA微球作为多剂量和单剂量疫苗接种的疫苗平台具有巨大潜力。